Clinical Trials / Research Studies
Craniopharyngioma

Craniopharyngioma

CONNECT1905: ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

  • Ages: 1 Year to 39 Years

Adamantinomatous Craniopharyngioma (ACP) is a highly debilitating pediatric brain tumor that lacks medical anti-tumor therapies. Current therapy, which depends largely on surgery and radiation, is associated with poor quality of life and becomes more challenging and risky in the setting of recurrent ...More

CONNECT2108: MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

  • Ages: 1 Year to 25 Years

MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug w ...More